Cardiff Oncology wins FDA Orphan Drug tag for onvansertib in CMML

The San Diego biotech's PLK1 inhibitor gains rare-disease benefits as Phase 1 data show preliminary efficacy in roughly 40% of myeloproliferative CMML patients.

A bright medical treatment room featuring a silver laser device poised over a white table, an examination bed with a blue sheet, and blurred medical equipment and white cabinets with shelves in the background.

Cardiff Oncology has secured FDA Orphan Drug Designation for onvansertib in chronic myelomonocytic leukaemia (CMML), adding a rare-disease regulatory credential to a PLK1 inhibitor already advancing toward a registrational trial in colorectal cancer.

The designation, announced on 21 October 2026, brings practical near-term benefits: tax credits for qualifying clinical trials, waiver of certain FDA user fees, and up to seven years of market exclusivity on approval. It does not, however, alter the standard regulatory review pathway or constitute an endorsement of clinical efficacy.

Preliminary clinical signals

The CMML programme is being evaluated in a Phase 1 investigator-initiated study in relapsed or refractory patients. Data presented at the 2025 American Society of Hematology Annual Meeting showed that onvansertib was relatively well tolerated as a monotherapy and produced clinical benefit in approximately 40% of myeloproliferative CMML patients in the dose-ranging cohort.

Responses in that cohort included a complete platelet normalisation, white blood cell count normalisation in a patient with a baseline count above 50 x 10^9/L, and a spleen response. One further patient achieved an optimal marrow response, with bone marrow blast reduction from 8% to 2%, enabling an allogeneic haematopoietic stem cell transplant; three additional patients experienced stable disease.

Mani Mohindru, President and Chief Executive Officer of Cardiff Oncology, said the designation "further validates the therapeutic potential of PLK1 inhibition in cancers with significant unmet need and adds to the growing body of evidence supporting this mechanism across both solid tumours and haematologic malignancies."

The scientific rationale for PLK1 inhibition in CMML is supported by published research linking RAS-pathway mutations, which are present in 40 to 50% of myeloproliferative CMML patients, to a KMT2A-PLK1 signalling axis. That mechanistic connection distinguishes onvansertib from cytoreductive agents and hypomethylating agents, which represent the current standard of care for most CMML patients.

Market context and competitive landscape

CMML is a rare and aggressive haematologic malignancy affecting primarily older adults; it carries features of both myelodysplastic syndromes and myeloproliferative neoplasms and carries a meaningful risk of transformation to acute myeloid leukaemia. The therapeutic options approved specifically for CMML remain narrow, with hydroxyurea and hypomethylating agents such as azacitidine and decitabine used off-label or with limited evidence. No PLK1 inhibitor has yet received regulatory approval in any haematologic malignancy.

Cardiff Oncology's primary commercial focus remains first-line RAS-mutated metastatic colorectal cancer, where a randomised Phase 2 trial has supported selection of a 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for a planned registrational study. The Orphan designation in CMML broadens the narrative around the PLK1 platform and could attract investigator interest, though the haematology programme remains early-stage and the company has not indicated plans for a company-sponsored Phase 2 in CMML.

Investors will note that onvansertib is simultaneously being assessed across a wide basket of tumour types, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer, largely through investigator-initiated trials rather than company-sponsored studies. That breadth of exploration is characteristic of mechanism-first oncology platforms but introduces execution risk given Cardiff Oncology's clinical-stage balance sheet. The next meaningful catalysts for the CMML indication will be updated Phase 1 data and any decision to initiate a company-sponsored expansion cohort.